Healthcare Pharmaceutical Biotech

Invitation to the Presentation of Cantargia's Interim Report for Q1 2026

May 6, 2026 4:20 AM

Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's interim report for Q1 2026 on Tuesday, May 19, 2026, at 07:00 a.m. CEST. In conjunction to the report, investors, analysts, and media are invited to an audiocast with teleconference (in English) on May 19, at 3:00 p.m. CEST, where Cantargia's CEO Hilde Steineger, and CFO Patrik Renblad, will present Cantargia and comment on the report, followed by a Q&A-session. If you wish...

Read more

New scientific Article Published on TrkA-NAM ACD137 Against Osteoarthritic Pain

May 6, 2026 4:20 AM

AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that a scientific article has been published on the preclinical characterization of ACD137, the lead drug candidate in the TrkA-NAM pain project. The scientific article, titled Analgesic, anti-inflammatory and joint protective effects of ACD137, a...

Read more

IRLAB Publishes Interim Report for The Period January - March 2026

May 6, 2026 1:20 AM

IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that the interim report for the period January-March 2026, has been published. KEY HIGHLIGHTS DURING AND AFTER THE FIRST QUARTER In January, IRLAB entered into a collaboration agreement with the Danish biotech company Biomia ApS to evaluate Biomia's drug candidates using IRLAB's research platform, the...

Read more

Onco-Innovations Announces Inka Health Collaborative Research to Advance Oncology Evidence Generation

May 5, 2026 6:00 PM

Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that Inka Health Corp. ("Inka Health"), the Company's wholly owned subsidiary, has started a collaborative research agreement (the "Agreement" or "Project" or "Work") with GlaxoSmithKline LLC ("GSK"). Under the Agreement, Inka Health and GSK intend to collaborate to develop real-world data-driven methodologies aimed at...

Read more

Big Cannabis Sold You a Lie. Now the Federal Government Is Giving It to Your Grandparents.

May 5, 2026 5:35 PM

They called it medicine. They said it could treat your anxiety, your pain, your PTSD, your insomnia, your opioid addiction, your cancer, your irritable bowel syndrome, your grief, your boredom, your sadness, and your shyness. They built billion dollar companies on those claims. They hired lobbyists, funded public relations campaigns, and placed their products in gleaming dispensaries designed to look like Apple Stores - all while knowing,...

Read more

Viemed Healthcare Announces First Quarter 2026 Financial Results

May 5, 2026 5:00 PM

Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, announced today that it has reported its financial results for the three months ended March 31, 2026, and updated guidance for the full year ending December 31, 2026. Operational highlights (all dollar amounts are USD): Net revenues for the quarter ended March 31, 2026 were...

Read more

Gala Health GLP-1 Review 2026: Compounded GLP-1 Access Is Changing - What to Verify on Pricing, FDA Status, and Refund Terms Before You Enroll

May 5, 2026 4:30 PM

Advertorial Disclosure: This article is sponsored advertorial content and may contain affiliate links. A commission may be earned if a reader enrolls through links in this article, at no additional cost to the reader. This content is for informational purposes only and does not constitute medical advice, a diagnosis, or a treatment recommendation. Gala GLP-1 is a telehealth platform; licensed healthcare providers independently evaluate...

Read more

Glucolyn Review: Truth Behind This Simple "Overnight Oatmeal Trick" Flattens High Blood Sugar To Know Before Buying!

May 5, 2026 4:20 PM

Disclaimers: This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. Compensation does not influence the verification standards applied. Statements about Glucolyn have not been evaluated by the Food and Drug Administration. Glucolyn is a dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease. A sponsored consumer information article on...

Read more

Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 5, 2026 4:05 PM

Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. "The first quarter of 2026 marked a series of landmark achievements for Protagonist, highlighted by the U.S. approval of ICOTYDE, FDA granting Priority Review for rusfertide, and advancement of our highly differentiated and fully-owned peptides PN-881 and PN-477,"...

Read more

Remote Pharmacy GLP-1 Program 2026: Compounded Semaglutide From $167/Month, No Subscription, No Hidden Fees - Pricing, Process, and What Patients Are Asking

May 5, 2026 2:00 PM

Paid Advertorial Disclosure: This article was produced in connection with a marketing arrangement and contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the reader. Medical Disclaimer: This article is for informational purposes only and is not medical advice. Prescription weight management medications require evaluation and a prescription from a licensed healthcare provider....

Read more

Trinity Meds GLP-1 Advertorial 2026: Compounded Semaglutide From $159, Tirzepatide From $259, FDA June 29 Deadline, and What to Know Before Enrolling

May 5, 2026 1:45 PM

Advertorial Disclosure: This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. This content is for informational purposes only and does not constitute medical advice, diagnosis, treatment, legal advice, or regulatory guidance. Prescription decisions are made by licensed clinicians, eligibility is not guaranteed, and compounded GLP-1 medications referenced in this...

Read more

Omni-Biotic Ranked #1 Probiotic Brand in Europe, Reflecting Strong Consumer Trust and Scientific Foundation

May 5, 2026 12:10 PM

Omni-Biotic U.S. announced today that Omni-Biotic has been ranked the #1 probiotic brand in Europe, based on IQVIA Consumer Health Customized Insight Study data. This distinction reflects the brand's leading position across European markets and underscores its continued expansion in the United States. In an increasingly competitive probiotic category, Omni-Biotic's leadership is driven by strong consumer adoption, practitioner endorsement, and a...

Read more

MilliporeSigma Receives 2026 Environment+Energy Leader Spotlight Award

May 5, 2026 11:00 AM

The 2026 Environment+Energy Leader Awards have recognized MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, for its commitment to preparing scientists to address sustainability through chemistry. The company received a Spotlight Award in the Collaboration category for its partnership with Beyond Benign, a leading green chemistry education non-profit devoted to empowering educators to transform chemistry...

Read more

Medical Care Technologies Inc. (OTC PINK:MDCE) Advances AI Platform Accuracy for Early Melanoma Detection

May 5, 2026 10:15 AM

Medical Care Technologies Inc. (OTC PINK:MDCE) ("MDCE" or the "Company"), an emerging developer of AI-powered health and wellness technologies, today announced that it is actively evaluating and integrating new advances in artificial intelligence to support the development of high accuracy dermatological imaging solutions focused on early-stage skin condition detection. Building upon its patent-pending imaging platform, the Company is...

Read more

Utah Medical Products, Inc. Announces Quarterly Dividend

May 5, 2026 10:00 AM

Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty-one cents ($.31) per share of common stock payable on July 3, 2026 to stockholders of record at the close of business on June 17, 2026. This is a 1.6% increase over the dividend declared in the same quarter of the prior year. Utah Medical Products, Inc., with particular interest in health care for women and their babies,...

Read more

RADIESSE(R) Receives FDA Approval for Décolleté Wrinkles as Dr. Rubinstein Provides Proven, FDA-Approved Solutions in New York and New Jersey

May 5, 2026 8:00 AM

Merz Aesthetics has announced that the FDA has approved RADIESSE® for the treatment of wrinkles in the décolleté area in patients 22 years of age or older - making it the first and only biostimulator in the United States approved for both the face and the body. This marks the fourth FDA-approved indication for RADIESSE, further cementing its position as one of the most versatile and clinically supported injectable treatments available in...

Read more

MEDIA ADVISORY: Grand Opening and Community Blood Drive Address Critical Local Need

May 5, 2026 8:00 AM

Advanced Health will host a community open house and blood drive on May 19, 2026, celebrating the opening of its new primary care office and reinforcing its commitment to improving access to high-quality, patient-centered care for the Greenville community. EVENT DETAILS What: Grand Opening + Community Blood Drive When: May 19, 2026 | 4 - 6 pm Where: 56 Pointe Circle, Suite 200 Greenville SC 29615 Who: Open to the public; media invited Offering...

Read more

AMC Health Appoints Sol Babani and Symbiosis Advisors as Strategic Advisor to Its Decentralized Clinical Trial Service Line

May 5, 2026 8:00 AM

AMC Health today announced the appointment of Sol Babani, Founder and CEO of Symbiosis Advisors, as Strategic Advisor to its newly established Decentralized Clinical Trial (DCT) service line. Babani will work closely with CEO Nesim Bildirici and Keith Tode, Executive Vice President of Decentralized Clinical Trials, to grow and operationalize AMC Health's DCT platform as it expands its modular operating partner offering to biopharmaceutical...

Read more

CBD Life Sciences Inc. (CBDL) Announces Launch of CBD Pouches Nicotine Free

May 5, 2026 7:00 AM

CBD Life Sciences Inc. (OTCID:CBDL) CBD Life Sciences Inc. is proud to announce our latest product CBD Pouches that are Nicotine Free. Our Tins Pouches are made for anyone looking for an easy, hassle-free way to enjoy the benefits without overcomplicating things. They offer a familiar chew-style experience with an added sense of relaxation-ideal for unwinding or making it through your day with less stress. Crafted from natural ingredients, these...

Read more

TherapyHive Featured in The New York Times for Its Innovative Therapist Office Rental Model

May 5, 2026 6:00 AM

TherapyHive, a flexible workspace and professional community for mental health professionals, has been featured in The New York Times for its innovative solution to the rising cost of therapy office space and the changing landscape of mental health care. The feature appeared in a New York Times business article examining how doctors and therapists are adapting to climbing commercial rents by finding creative ways to share or sublease office...

Read more